INBX

Conviction 64HealthcareScan · Thu, Sep 24, 2026

Inhibrx Biosciences, Inc. (INBX) closed at $100.39 (+0.05%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 42, RS Rating 99, -29.2% from its 52-week high, +33.8% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

INBX$100.39+0.05%

ResistanceSupportVol 14Insider buyInsider sell

Vol MA14 409.8K

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Inhibrx Biosciences, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.inhibrx.com ↗

Price100.39

Change+0.05%

Gap+0.90%

Rel volume0.51×

Avg volume364.8K

Avg $ vol41.34M

SMA 20113.52

SMA 50100.34

SMA 20090.59

Price vs 50+0.05%

Price vs 200+10.81%

MA stackbullish

50/200 cross—

Supertrenddown · 125.44

RSI (14)42

MACD hist-2.16

MACD cross—

Stoch %K / %D18 / 28

ADX (14)19

+DI / −DI22 / 30

RSI divergence—

MACD divergence—

ATR %7.85%

ADR %6.97%

52w high141.84

52w low28.36

From 52w high-29.23%

Above 52w low+253.97%

New 52w highNo

SqueezeOff

Bollinger width30.05%

%B0.12

Donchian pos17.80%

Donchian high129.88

Donchian low94.00

AVWAP (52w high)107.98

vs AVWAP high-7.03%

AVWAP (52w low)90.25

vs AVWAP low+11.23%

OBV trendDown

Chaikin MF (20)-0.03

Today vs 20d0.51×

Avg vol (14d)409.8K

Avg vol (20d)364.8K

Avg $ vol (20d)41.34M

Market cap1.48B

RS Rating99 / 99

RS 3m (vs SPY)+0.83%

RS 6m (vs SPY)+34.23%

RS line new highNo

Trend template7/8

Technical rank67.1

1 week-4.15%

1 month-18.20%

3 months+5.32%

6 months+51.05%

1 year+247.35%

YTD+33.78%

P/E-10.55

P/B-27.89

P/S—

P/FCF-11.38

EPS-9.04

Div yield—

ROE264.37%

ROA-90.81%

Debt/Eq-3.33

Current5.07

EV/EBITDA-11.47

Gross margin—

Net margin—

Rev growth550.00%

EPS growth-108.30%

Price target266.67

Target upside165.65%

Analyst ratingBuy

Institutional101.88%

Ent. value1.52B

Revenue0

Net income-36.65M

Gross profit—

Free cash flow-129.82M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out14.67M

Employees110

ListedTue, May 28, 2024

Free float7.71M

Float %53.0%

Short interest3.3M

Days to cover10.4d

Short volume49.9%

Squeeze score72 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$2.34 vs −$2.50

Last surprise+6.4% beat

Setup gradeB

Conviction64 / 100

Pattern quality—

Tech rank67.1 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance130.45

Support82.74

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in INBX

All disclosures →

No recent disclosed trades by Congress in INBX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in INBX · open-market 2 buys · 3 sells

Insider	Side	Shares	Value	Traded	Filed
Kayyem Jon Faiz Director · Common Stock · 2026-09-23	Buy	5K	$500K	2026-09-23	2026-09-23
Kayyem Jon Faiz Director · Common Stock · 2026-09-16	Buy	5K	$500K	2026-09-16	2026-09-17
MANHARD KIMBERLY Director · Common Stock · 2026-09-15	Sell	500	$53K	2026-09-15	2026-09-15
MANHARD KIMBERLY Director · Common Stock · 2026-09-14	Sell	500	$55K	2026-09-14	2026-09-15
MANHARD KIMBERLY Director · Common Stock · 2026-09-11	Sell	500	$56K	2026-09-11	2026-09-15
MANHARD KIMBERLY Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
Kayyem Jon Faiz Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
Vuori Kristiina MD Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
FORSYTH DOUGLAS Director · Stock Option (right to buy) · 2026-06-03	Grant	15K	$0	2026-06-03	2026-06-04
Matly David President · Stock Option (right to buy) · 2026-04-24	Grant	50K	$0	2026-04-24	2026-04-27

SEC filings

EDGAR filings in INBX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.